Podium Presentation Meniscus

24.1.2 - Synthetic Medial Meniscus Replacement Superior to Non-Surgical Control: 3-Year RCT Results (Pre-Recorded)

Presentation Topic
Meniscus
Date
15.04.2022
Lecture Time
11:09 - 11:18
Room
Potsdam 1
Session Name
Session Type
Free Papers
Speaker
  • P. Verdonk (Gent-Zwijnaarde, BE)
Authors
  • W. Gersoff (Denver, US)
  • A. Gomoll (New York, US)
  • S. Hacker (La Mesa, US)
  • E. Hershman (New York, US)
Disclosure
W. Gersoff & S. Hacker, Active Implants, Paid training instructors of the NUsurface surgical technique to new surgeons E. Hershman, Active Implants, Medical Director of MERCURY Clinical Study

Abstract

Purpose

This research longitudinally tests the clinical trial hypothesis that investigational subjects realize superior improvements in knee-related pain, function, and quality of life, to control subjects, through 3 years of follow-up.

Methods and Materials

242 subjects (176 investigational, 66 control) treated in 2 prospective, concurrent clinical trials in the U.S., and pooled for analysis. Subjects had persistent knee pain and one or more previous partial meniscectomies at least 6 months before trial entry. Patient-reported knee pain, function, and quality of life were assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Treatment cessation was defined as any investigational subject discontinuing the per-protocol treatment by permanent prosthesis removal, or control subjects undergoing any surgical procedure on the index knee. The investigational and control cohorts analyzed were compared at each time point using a two tailed t-test.

Results

The magnitude of improvement from baseline to 3 years was statistically superior in the investigational cohort, compared to the control cohort for all 6 KOOS subscales (Figure 1). Improvement in KOOS Overall and KOOS Pain for the investigational and control cohorts at 3 years were 26.4 vs 10.4 points, and 26.9 vs 15.4 points, respectively. Controls experienced a 35% decline in KOOS Overall improvement between the 2-year and 3-year timepoint (15.9 declined to 10.4). Treatment cessation through 3 years was 31% higher in the control cohort than the investigational cohort (19.6% vs.15.0%).

2022 icrs figure 1.png

Conclusion

Results demonstrate statistically and clinically significant superiority for relief of knee pain and improvement in function compared to non-surgical care alone. Between 2 and 3 years, NUsurface KOOS scores remained stable, while Controls regressed. The magnitude of change from baseline to 3 years remained superior for the investigational cohort, even when accounting for subjects undergoing device exchange or repositioning.

Collapse